ok - i get it - so it will eventually replace SOC.
No I don't think that is low risk, I think there is a lot of things that need to go right for that to happen and many many years of development. Just looking at the efficacy rates of first line and second line therapy for DLCBC. Azer cell would have to peform better, significantly better than 57% CR in the future for it to move up in the ranks of therapy in that indication.
No I am not saying there is not a pool of patients for Azer cell or that there is no money there at all - but for SOC I see a great deal of risk and hurdles to go.
Heck there are enough hurdles at the moment just getting it to registration and commercialised as third line therapy.
I think
IMU Price at posting:
4.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)